Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators

por Scheer, Justin M., Sandoval, Wendy, Elliott, J. Michael, Shao, Lily, Luis, Elizabeth, Lewin-Koh, Sock-Cheng, Schaefer, Gabriele, Vandlen, Richard
Publicado 2012

High cell-surface density of HER2 deforms cell membranes

por Chung, Inhee, Reichelt, Mike, Shao, Lily, Akita, Robert W., Koeppen, Hartmut, Rangell, Linda, Schaefer, Gabriele, Mellman, Ira, Sliwkowski, Mark X.
Publicado 2016

Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model

por Kirouac, Daniel C., Schaefer, Gabriele, Chan, Jocelyn, Merchant, Mark, Orr, Christine, Huang, Shih-Min A., Moffat, John, Liu, Lichuan, Gadkar, Kapil, Ramanujan, Saroja
Publicado 2017

Erratum: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model

por Kirouac, Daniel C., Schaefer, Gabriele, Chan, Jocelyn, Merchant, Mark, Orr, Christine, Huang, Shih-Min A., Moffat, John, Liu, Lichuan, Gadkar, Kapil, Ramanujan, Saroja
Publicado 2017

Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action

por Chan, Jocelyn, Chan, Joyce, Shao, Lily, Stawicki, Scott S., Pham, Victoria C., Akita, Rob W., Hafner, Marc, Crocker, Lisa, Yu, Kebing, Koerber, James T., Schaefer, Gabriele, Comps-Agrar, Laetitia
Publicado 2022

NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma

por Hegde, Ganapati V, de la Cruz, Cecile, Giltnane, Jennifer M, Crocker, Lisa, Venkatanarayan, Avinashnarayan, Schaefer, Gabriele, Dunlap, Debra, Hoeck, Joerg D, Piskol, Robert, Gnad, Florian, Modrusan, Zora, de Sauvage, Frederic J, Siebel, Christian W, Jackson, Erica L
Publicado 2019

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

por Merchant, Mark, Moffat, John, Schaefer, Gabriele, Chan, Jocelyn, Wang, Xi, Orr, Christine, Cheng, Jason, Hunsaker, Thomas, Shao, Lily, Wang, Stephanie J., Wagle, Marie-Claire, Lin, Eva, Haverty, Peter M., Shahidi-Latham, Sheerin, Ngu, Hai, Solon, Margaret, Eastham-Anderson, Jeffrey, Koeppen, Hartmut, Huang, Shih-Min A., Schwarz, Jacob, Belvin, Marcia, Kirouac, Daniel, Junttila, Melissa R.
Publicado 2017

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

por Merchant, Mark, Moffat, John, Schaefer, Gabriele, Chan, Jocelyn, Wang, Xi, Orr, Christine, Cheng, Jason, Hunsaker, Thomas, Shao, Lily, Wang, Stephanie J., Wagle, Marie-Claire, Lin, Eva, Haverty, Peter M., Shahidi-Latham, Sheerin, Ngu, Hai, Solon, Margaret, Eastham-Anderson, Jeffrey, Koeppen, Hartmut, Huang, Shih-Min A., Schwarz, Jacob, Belvin, Marcia, Kirouac, Daniel, Junttila, Melissa R.
Publicado 2018

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

por Hanan, Emily J., Eigenbrot, Charles, Bryan, Marian C., Burdick, Daniel J., Chan, Bryan K., Chen, Yuan, Dotson, Jennafer, Heald, Robert A., Jackson, Philip S., La, Hank, Lainchbury, Michael D., Malek, Shiva, Purkey, Hans E., Schaefer, Gabriele, Schmidt, Stephen, Seward, Eileen M., Sideris, Steve, Tam, Christine, Wang, Shumei, Yeap, Siew Kuen, Yen, Ivana, Yin, Jianping, Yu, Christine, Zilberleyb, Inna, Heffron, Timothy P.
Publicado 2014